Association of dynamic susceptibility contrast enhanced MR Perfusion parameters with prognosis in elderly patients with glioblastomas

[1]  Jill S. Barnholtz-Sloan,et al.  Epidemiologic and Molecular Prognostic Review of Glioblastoma , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[2]  L. Deangelis,et al.  Glioblastoma and other malignant gliomas: a clinical review. , 2013, JAMA.

[3]  B. Rosen,et al.  Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation , 2013, Proceedings of the National Academy of Sciences.

[4]  R. Stupp,et al.  Optimal management of elderly patients with glioblastoma. , 2013, Cancer treatment reviews.

[5]  Tao Jiang,et al.  Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. , 2013, Cancer letters.

[6]  Serdar Bozdag,et al.  Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levels. , 2013, PloS one.

[7]  David Gutman,et al.  Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. , 2013, Radiology.

[8]  T. Cloughesy,et al.  Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy , 2013, Current Neurology and Neuroscience Reports.

[9]  Joseph A. Hanson,et al.  Antivascular endothelial growth factor antibody for treatment of glioblastoma multiforme. , 2013, The Permanente journal.

[10]  C. Grommes,et al.  Bevacizumab for the treatment of high-grade glioma , 2012, Expert opinion on biological therapy.

[11]  G. Reifenberger,et al.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[12]  J. Boxerman,et al.  The Role of Preload and Leakage Correction in Gadolinium-Based Cerebral Blood Volume Estimation Determined by Comparison with MION as a Criterion Standard , 2012, American Journal of Neuroradiology.

[13]  W. Mason,et al.  Management of glioblastoma in the elderly. , 2012, Clinical advances in hematology & oncology : H&O.

[14]  F. Giangaspero,et al.  Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. , 2012, International journal of radiation oncology, biology, physics.

[15]  Gordon Li,et al.  Pathology: commonly monitored glioblastoma markers: EFGR, EGFRvIII, PTEN, and MGMT. , 2012, Neurosurgery clinics of North America.

[16]  Tracy T Batchelor,et al.  Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. , 2012, Cancer research.

[17]  Y. Yamada,et al.  Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional status , 2010, Journal of Neuro-Oncology.

[18]  S. Grossman,et al.  Treatment of Glioblastoma in “Elderly” Patients , 2011, Current treatment options in oncology.

[19]  Samuel T Chao,et al.  Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases. , 2011, Neuro-oncology.

[20]  E. Melhem,et al.  Differentiation between Glioblastomas, Solitary Brain Metastases, and Primary Cerebral Lymphomas Using Diffusion Tensor and Dynamic Susceptibility Contrast-Enhanced MR Imaging , 2011, American Journal of Neuroradiology.

[21]  T. Mikkelsen,et al.  In Vivo Correlation of Tumor Blood Volume and Permeability with Histologic and Molecular Angiogenic Markers in Gliomas , 2011, American Journal of Neuroradiology.

[22]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[23]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Nelson,et al.  Bevacizumab and chemotherapy for recurrent glioblastoma , 2009, Neurology.

[25]  T. Hirai,et al.  Prognostic Value of Perfusion MR Imaging of High-Grade Astrocytomas: Long-Term Follow-Up Study , 2008, American Journal of Neuroradiology.

[26]  Douglas C. Miller,et al.  Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2008, Radiology.

[27]  D. Caldiroli,et al.  Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. , 2008, Neuro-oncology.

[28]  Susan M. Chang,et al.  Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy , 2008, Journal of Neuro-Oncology.

[29]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[30]  Glyn Johnson,et al.  Measuring blood volume and vascular transfer constant from dynamic, T  2* ‐weighted contrast‐enhanced MRI , 2004, Magnetic resonance in medicine.

[31]  M. Strawderman,et al.  Proliferation index is related to patient age in glioblastoma , 2001, Neurology.

[32]  M Takahashi,et al.  Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. , 1998, AJR. American journal of roentgenology.

[33]  P. Black,et al.  Microvessel density is a prognostic indicator for patients with astroglial brain tumors , 1996, Cancer.

[34]  B. Rosen,et al.  Perfusion imaging with NMR contrast agents , 1990, Magnetic resonance in medicine.